US20070255253A1 - Activatable bioactive vascular occlusive device and method of use - Google Patents
Activatable bioactive vascular occlusive device and method of use Download PDFInfo
- Publication number
- US20070255253A1 US20070255253A1 US11/821,340 US82134007A US2007255253A1 US 20070255253 A1 US20070255253 A1 US 20070255253A1 US 82134007 A US82134007 A US 82134007A US 2007255253 A1 US2007255253 A1 US 2007255253A1
- Authority
- US
- United States
- Prior art keywords
- vascular occlusive
- agent
- bioactive agent
- aneurysm
- bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
- A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/1214—Coils or wires
- A61B17/1215—Coils or wires comprising additional materials, e.g. thrombogenic, having filaments, having fibers, being coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
- A61B17/12186—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices liquid materials adapted to be injected
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
Definitions
- the present invention relates to medical implantable device, and more particularly, to a vascular occlusive device, such as an embolic coil for occluding an aneurysm, which includes a bioactive coating placed on the occlusive device for reacting with bodily tissue in order to promote a desired result, for example promoting an increase of tissue growth into the occlusive device.
- a vascular occlusive device such as an embolic coil for occluding an aneurysm
- a bioactive coating placed on the occlusive device for reacting with bodily tissue in order to promote a desired result, for example promoting an increase of tissue growth into the occlusive device.
- vasculature occlusive devices have been placed within the vasculature of the human body to occlude, or partially occlude, blood flow through the vasculature. Additionally, such devices have been introduced into aneurysms in order to fill, or partially fill, the aneurysm so as to reduce the pressure which is applied to the interior of the aneurysm in order to prevent further growth or expansion of the aneurysm.
- These devices may take the form of a coil, such as a helical coil, and are typically placed within the vessel or aneurysm by use of a delivery catheter which is inserted into the vessel and positioned such that the distal end of the delivery catheter is adjacent to a selected site for placement.
- Occlusive devices which take the form of coils may be helically wound coils, random wound coils, coils wound within coils or other such coil configurations. Examples of various coil configurations are disclosed in U.S. Pat. No. 5,334,210, entitled, “Vascular Occlusion Assembly” and U.S. Pat. No. 5,382,259, entitled, “Vasoocclusion Coil With Attached Tubular Woven Or Braided Fibrous Covering.” Such coils are generally formed from radiopaque metallic materials, such as platinum, gold, tungsten or alloys of these metals.
- embolic coils have been placed within the distal end of a delivery catheter and when the distal end of the catheter is properly positioned, the coil may then be pushed out of the end of the catheter with, for example a guidewire, to release the coil at the desired location.
- This procedure of placement of the embolic coil is conducted under fluoroscopic visualization such that the movement of the coil may be monitored and the coil may be placed at a desired location.
- such coils have been specifically designed to be stretch resistant, such as the vasculature occlusive coil disclosed in U.S. Pat. No. 5,853,418, entitled, “Stretch Resistant Vaso-Occlusive Coils (II)” which discloses a helically wound coil having a polymeric stretch resistant member extending through the lumen of the coil and fixedly attached to both ends of the coil to prevent the coil from stretching.
- stretch resistant such as the vasculature occlusive coil disclosed in U.S. Pat. No. 5,853,418, entitled, “Stretch Resistant Vaso-Occlusive Coils (II)” which discloses a helically wound coil having a polymeric stretch resistant member extending through the lumen of the coil and fixedly attached to both ends of the coil to prevent the coil from stretching.
- U.S. Pat. No. 5,980,550 entitled, “Water-Soluble Coating For Bioactive Vasoocclusive Devices,” discloses an embolic coil having an inner coating which serves as a thrombogenic agent and an outer coating of a water soluble agent which dissolves after placement of the coil in order expose the thrombogenic inner coating to enhance the growth of thrombus into an around the coil.
- the water soluble coating prevents the thrombogenic inner coating from coming into contact with the surrounding blood until the water soluble coating is dissolved by contact with blood which is comprised largely of water.
- vasculature occlusive device includes an agent for enhancing thromboginicity of the device and also includes an outer coating to prevent such activity until the outer coating is dissolved by blood flow, there is no control over when the dissolving process begins and therefore no control over the time in which the thrombogenic agent becomes activated. Without such control, it is possible that thrombus can begin forming on the coil prior to the time the coil is properly placed within a vessel, or aneurysm, therefore making it very difficult if not impossible to reposition, or remove, the improperly placed coil. Alternatively, with water soluble outer protective coating the passive process of removing the outer coating may be so slow that the reaction may not occur in a timely manner.
- a vascular occlusive device such as an embolic coil for treating an aneurysm
- a support member which may take the form of a helical coil
- a bioactive agent which is disposed on the support member
- an outer barrier which is disposed on the bioactive agent to prevent contact between the bioactive agent and a bodily fluid when the vasculature occlusive device is inserted into a blood vessel or aneurysm.
- the outer barrier exhibits the characteristic of being inert to bodily fluid, but dissolves upon being exposed to an external agent.
- the external agent may take the form of a liquid medium which may be injected into the blood vessel or aneurysm.
- the bioactive agent takes the form of a coating which is applied to the support member and which serves to enhance a reaction of the body, such as for example the growth of thrombus, into and around the vasculature occlusive device.
- the outer barrier takes the form of an outer coating applied to the bioactive agent and prevents bodily fluid, such as blood, from reacting with the bioactive agent until such time as the outer barrier is exposed to an external agent.
- the external agent may take the form of a solvent which when applied to the outer barrier causes the outer barrier to dissolve away from the bioactive agent.
- an embolic coil for treating an aneurysm which is coated with a thrombogenic agent, or an agent which increases or promotes the growth of thrombus material, and an outer coating applied to the thrombogenic coating which prevents a reaction between blood and the thrombogenic agent until such time as an external agent is applied to the outer coating to thereby cause this coating to dissolve away from the thrombogenic coating.
- a method for treating an aneurysm which includes the steps of inserting a vascular occlusive device which comprises a support member, a bioactive agent disposed on the support member, and an outer coating disposed on the bioactive agent which outer coating exhibits the characteristic of dissolving to uncover at least a portion of the bioactive agent when an external medium is applied to the outer coating.
- the method also includes the steps of inserting the vascular occlusive device into a blood vessel, or an aneurysm, and, upon election, applying an external medium to the outer coating to thereby cause the outer coating to dissolve and expose at least a portion, or all, of the bioactive agent to thereby cause a desired reaction between the body and the vascular occlusive device.
- the method includes the steps of providing a vasculature occlusive coil which has a thrombus inducing surface and which is coated with an outer coating which exhibits the characteristics of dissolving to expose at least a portion of the thrombogenic material when an external agent is applied to the outer coating.
- This method step also includes the steps of inserting the vasculature occlusive device into a blood vessel or an aneurysm, and then upon election, applying an external agent to the outer coating to thereby cause the outer coating to dissolve and expose at least a portion of the thrombogenic surface of the vasculature occlusive device.
- FIG. 1 is an elevational view of an embolic coil illustrating a vascular occlusive coil in accordance with one embodiment of the present invention
- FIG. 2 is an elevational view, partly in cross-section of the vascular occlusive coil as shown in FIG. 1 illustrating a bioactive coating and an outer barrier coating in accordance with the embodiment of the present invention
- FIGS. 3A through 3C illustrate the method steps of applying multiple vascular occlusive coils as shown in FIG. 1 into an aneurysm and thereafter applying an external agent to thereby activate the embolic coils.
- FIGS. 1 and 2 illustrate a vascular occlusive device which takes the form of an embolic coil 10 which may be placed along with other similar coils into a blood vessel or into an aneurysm in order to partially fill the aneurysm.
- the embolic coil 10 is a typical embolic coil which comprises a helically wound coil 12 formed from a platinum alloy wire wound into a helical configuration.
- the diameter of the wire is generally in the range of about 0.0007 inches to about 0.008 inches and the outer diameter of the coil 12 is preferably in a range of about 0.003 inches to about 0.055 inches.
- the particular embolic coil 12 illustrated in FIGS. 1 and 2 is shown as being a straight, helically wound coil, it should be appreciated that embolic coils are formed in various configurations and may take the form of a helix, a random shaped configuration or even a coil within a coil.
- the embolic coil 10 includes a weld bead 14 which is attached to the distal end of the coil for providing a less traumatic distal end for the embolic coil 10 .
- the embolic coil 10 includes a cylindrical headpiece 16 which is placed into the lumen of the helically wound coil 12 at the proximal end of the coil and is held in place by an adhesive material 18 interposed between the cylindrical headpiece 16 and the helical coil 12 .
- the construction of the embolic coil 10 and an associated hydraulic deployment system for placing the embolic coil within an aneurysm is disclosed in more detail in U.S. patent application Ser. No. 10/102,154, entitled, “Small Diameter Embolic Coil Hydraulic Deployment System,” filed Mar. 19, 2002, assigned to the same assignee of the present invention and is hereby incorporated by reference.
- FIG. 2 illustrates in more detail a bioactive agent 20 , and an outer barrier 22 which is disposed upon the bioactive agent 20 for preventing the activation of the bioactive agent until such time as an election is made to activate the bioactive agent.
- the bioactive agent 20 which may take the form of a thrombogenic agent, i.e. an agent which serves to increase or promote the growth and adhesion of thrombus onto the surface of the embolic coil 10 , is coated onto the outer surface of the coil 12 . While the bioactive agent may take the form of a thrombogenic agent, it should be understood that the bioactive agent may take any form which would induce a desired reaction bodily tissue.
- the bioactive agent may serve to cause blood to clot onto the surface of the embolic coil 10 , it may serve to enhance the adhesion of thrombus onto the surface of the embolic coil, or it may serve to cause adjacent embolic coils to become bonded to each other through adhesion by components of blood. It should be appreciated that there are many other reactions which might exist between the bioactive agent and bodily tissue which would be desirable.
- the outer barrier 22 takes the form of a coating which is disposed upon the bioactive agent 20 and serves to insulate the bioactive agent from adjacent bodily fluid until such time as a decision is made by a physician to activate the outer barrier 22 .
- the outer barrier 22 takes the form of a material which is inert to bodily fluid, but which dissolves and exposes the bioactive agent 20 when the outer barrier 22 is subjected to an external agent.
- the bioactive agent 20 is comprised of polyglycolic acid
- the outer barrier 22 is comprised of ethylene vinyl alcohol
- the external agent for dissolving the outer barrier 22 is dimethyl sulfoxide (DMSO) which serves to dissolve the outer barrier 22 to thereby expose the bioactive agent 20 .
- DMSO dimethyl sulfoxide
- the external agent be inert to bodily fluids, such as being non-water soluble, such as blood, in order to prevent the outer barrier 22 from dissolving and exposing the bioactive agent 20 until such time as an election is made by a physician to activate the outer barrier 22 .
- FIGS. 3A through 3C generally illustrate a method of utilizing the present invention. More particularly, FIG. 3A illustrates a delivery catheter 24 having an embolic coil 10 placed in the distal end of the catheter for delivery into an aneurysm 26 .
- FIG. 3B illustrates the delivery catheter 24 being used to position multiple vascular occlusive coils including a final embolic coil 28 into the aneurysm 26 .
- FIG. 3C illustrates the application of an external agent 30 , which may take the form of a solvent for dissolving the outer barrier 22 to thereby activate the outer barrier 22 to expose at least a portion of the bioactive agent 20 .
- the physician may determine at what point in time during the process of “filling” an aneurysm the physician elects to activate a coil as opposed to having no control over the time in which the coils become activated.
- the bioactive agent may take the form of any material or surface which when placed into the body causes or inhibits a reaction with a bodily substance.
- the bioactive agent may be a thrombus inducing material, or surface when placed within a blood vessel induces the growth of thrombus onto the surface of the bioactive agent or where the bioactive agent is a thrombolitic agent to inhibit the growth of tissue.
- the bioactive agent could take the form of a material which causes blood to clot onto the surface of the material, a material which produces an immune response, a material which releases a human growth factor, a material which promotes endothelization, etcetera.
- bioactive agent is a pharmacologic agent which is inactive until the barrier is dissolved, or removed, or is modified, by an external source to expose the pharmacological agent to the body.
- a preferred bioactive agent to be used with a vascular occlusive coil is polyglycolic acid which promotes the growth of tissue.
- the outer barrier may take the form of a coating applied to the bioactive agent, or a substance added to the bioactive agent, which causes the bioactive agent to be substantially non-reactive with bodily fluids until such time as the outer barrier is acted upon by an external agent.
- a preferred outer barrier to be used with a vascular occlusive coil is a coating of ethylene vinyl alcohol which serves to encase the bioactive agent until a solvent is applied to the coating to thereby dissolve, or remove, or modify the barrier in order to expose the bioactive agent to the body.
- the external agent may take the form of any agent which when applied to the outer barrier causes the outer barrier to become ineffective in preventing a reaction between the bioactive agent and bodily tissue.
- the external agent may take the form of a solvent for dissolving the outer barrier in order to expose the bioactive agent, or it may take the form of a substance which reacts with the bioactive agent in order to activate the bioactive agent.
- the external agent may for example be a liquid material or it may be a source of heat or a laser source for dissolving the outer barrier, or removing all or part of the outer barrier or for modifying the outer barrier such as for example biologically modifying the outer barrier in order to activate receptors of the bioactive agent, in order to expose the bioactive agent to bodily tissue.
- a preferred external agent for a vascular occlusive coil is dimethyl sulfoxide which serves as a solvent to dissolve an outer barrier coating comprising ethylene vinyl alcohol so as to permit the bioactive agent to come into contact with bodily tissue.
- bodily tissue is meant any substance within the human body and includes blood, fibrous growth within blood vessels, etcetera.
Abstract
A vascular occlusive device which includes a vascular occlusive embolic coil, a bioactive coating disposed onto the embolic coil, and an outer barrier coating which serves to prevent a reaction between the bioactive agent in the bioactive coating and bodily fluids, until the outer barrier is activated by applying an external agent to the outer barrier.
Description
- This patent application is a divisional of U.S. non-provisional patent application Ser. No. 10/738,473 entitled “Activatable Bioactive Vascular Occlusive Device and Method Of Use”, filed Dec. 17, 2003.
- 1. Field of the Invention
- The present invention relates to medical implantable device, and more particularly, to a vascular occlusive device, such as an embolic coil for occluding an aneurysm, which includes a bioactive coating placed on the occlusive device for reacting with bodily tissue in order to promote a desired result, for example promoting an increase of tissue growth into the occlusive device.
- 2. Description of the Prior Art
- For many years vasculature occlusive devices have been placed within the vasculature of the human body to occlude, or partially occlude, blood flow through the vasculature. Additionally, such devices have been introduced into aneurysms in order to fill, or partially fill, the aneurysm so as to reduce the pressure which is applied to the interior of the aneurysm in order to prevent further growth or expansion of the aneurysm. These devices may take the form of a coil, such as a helical coil, and are typically placed within the vessel or aneurysm by use of a delivery catheter which is inserted into the vessel and positioned such that the distal end of the delivery catheter is adjacent to a selected site for placement. Once the occlusive device is placed within a blood vessel or aneurysm, surrounding tissue reacts with the “foreign” object and begins to grow into and around the device to provide more complete occlusion of the vessel.
- Examples of such delivery catheters are disclosed in U.S. Pat. No. 5,108,407, entitled “Method And Apparatus For Placement Of An Embolic Coil” and U.S. Pat. No. 5,122,136, entitled “Endovascular Electrolytically Detachable Guidewire Tip For The Electroformation Of Thrombus In Arteries, Veins, Aneurysms, Vascular Malformations And Arteriovenous Fistulas.” These patents disclose catheter systems for delivering embolic coils to preselected positions within Vessels of the human body in order to treat aneurysms, or alternatively, to occlude a blood vessel at a preselected location.
- Occlusive devices which take the form of coils may be helically wound coils, random wound coils, coils wound within coils or other such coil configurations. Examples of various coil configurations are disclosed in U.S. Pat. No. 5,334,210, entitled, “Vascular Occlusion Assembly” and U.S. Pat. No. 5,382,259, entitled, “Vasoocclusion Coil With Attached Tubular Woven Or Braided Fibrous Covering.” Such coils are generally formed from radiopaque metallic materials, such as platinum, gold, tungsten or alloys of these metals. Oftentimes several coils are placed at a given location within a vessel, or within an aneurysm, to more completely occlude, or partially occlude, the flow of blood through the vessel or aneurysm. Thrombus growth onto the coils further enhances the occlusive effect of the coils.
- In the past, embolic coils have been placed within the distal end of a delivery catheter and when the distal end of the catheter is properly positioned, the coil may then be pushed out of the end of the catheter with, for example a guidewire, to release the coil at the desired location. This procedure of placement of the embolic coil is conducted under fluoroscopic visualization such that the movement of the coil may be monitored and the coil may be placed at a desired location.
- In addition, such coils have been specifically designed to be stretch resistant, such as the vasculature occlusive coil disclosed in U.S. Pat. No. 5,853,418, entitled, “Stretch Resistant Vaso-Occlusive Coils (II)” which discloses a helically wound coil having a polymeric stretch resistant member extending through the lumen of the coil and fixedly attached to both ends of the coil to prevent the coil from stretching.
- In order to increase the thrombogenicity of an embolic coil, such coils have included a coating, such as collagen, which is applied to the surface of the coil. This concept is disclosed in U.S. Pat. No. 5,690,671, entitled, “Embolic Elements And Methods And Apparatus For Their Delivery,” which discloses such a collagen coated embolic coil.
- In addition, U.S. Pat. No. 5,980,550, entitled, “Water-Soluble Coating For Bioactive Vasoocclusive Devices,” discloses an embolic coil having an inner coating which serves as a thrombogenic agent and an outer coating of a water soluble agent which dissolves after placement of the coil in order expose the thrombogenic inner coating to enhance the growth of thrombus into an around the coil.
- The water soluble coating prevents the thrombogenic inner coating from coming into contact with the surrounding blood until the water soluble coating is dissolved by contact with blood which is comprised largely of water.
- While the vasculature occlusive device disclosed in this patent includes an agent for enhancing thromboginicity of the device and also includes an outer coating to prevent such activity until the outer coating is dissolved by blood flow, there is no control over when the dissolving process begins and therefore no control over the time in which the thrombogenic agent becomes activated. Without such control, it is possible that thrombus can begin forming on the coil prior to the time the coil is properly placed within a vessel, or aneurysm, therefore making it very difficult if not impossible to reposition, or remove, the improperly placed coil. Alternatively, with water soluble outer protective coating the passive process of removing the outer coating may be so slow that the reaction may not occur in a timely manner.
- In accordance with one aspect of the present invention, there is provided a vascular occlusive device, such as an embolic coil for treating an aneurysm, which includes a support member which may take the form of a helical coil, a bioactive agent which is disposed on the support member, and an outer barrier which is disposed on the bioactive agent to prevent contact between the bioactive agent and a bodily fluid when the vasculature occlusive device is inserted into a blood vessel or aneurysm. The outer barrier exhibits the characteristic of being inert to bodily fluid, but dissolves upon being exposed to an external agent. The external agent may take the form of a liquid medium which may be injected into the blood vessel or aneurysm.
- In accordance with another aspect of the present invention, the bioactive agent takes the form of a coating which is applied to the support member and which serves to enhance a reaction of the body, such as for example the growth of thrombus, into and around the vasculature occlusive device. The outer barrier takes the form of an outer coating applied to the bioactive agent and prevents bodily fluid, such as blood, from reacting with the bioactive agent until such time as the outer barrier is exposed to an external agent. The external agent may take the form of a solvent which when applied to the outer barrier causes the outer barrier to dissolve away from the bioactive agent.
- In accordance with still another aspect of the present invention, there is provided an embolic coil for treating an aneurysm which is coated with a thrombogenic agent, or an agent which increases or promotes the growth of thrombus material, and an outer coating applied to the thrombogenic coating which prevents a reaction between blood and the thrombogenic agent until such time as an external agent is applied to the outer coating to thereby cause this coating to dissolve away from the thrombogenic coating.
- In accordance with still another aspect of the present invention, there is provided a method for treating an aneurysm which includes the steps of inserting a vascular occlusive device which comprises a support member, a bioactive agent disposed on the support member, and an outer coating disposed on the bioactive agent which outer coating exhibits the characteristic of dissolving to uncover at least a portion of the bioactive agent when an external medium is applied to the outer coating. The method also includes the steps of inserting the vascular occlusive device into a blood vessel, or an aneurysm, and, upon election, applying an external medium to the outer coating to thereby cause the outer coating to dissolve and expose at least a portion, or all, of the bioactive agent to thereby cause a desired reaction between the body and the vascular occlusive device.
- In accordance with still another aspect of the present invention, the method includes the steps of providing a vasculature occlusive coil which has a thrombus inducing surface and which is coated with an outer coating which exhibits the characteristics of dissolving to expose at least a portion of the thrombogenic material when an external agent is applied to the outer coating. This method step also includes the steps of inserting the vasculature occlusive device into a blood vessel or an aneurysm, and then upon election, applying an external agent to the outer coating to thereby cause the outer coating to dissolve and expose at least a portion of the thrombogenic surface of the vasculature occlusive device.
-
FIG. 1 is an elevational view of an embolic coil illustrating a vascular occlusive coil in accordance with one embodiment of the present invention; -
FIG. 2 is an elevational view, partly in cross-section of the vascular occlusive coil as shown inFIG. 1 illustrating a bioactive coating and an outer barrier coating in accordance with the embodiment of the present invention; -
FIGS. 3A through 3C illustrate the method steps of applying multiple vascular occlusive coils as shown inFIG. 1 into an aneurysm and thereafter applying an external agent to thereby activate the embolic coils. -
FIGS. 1 and 2 illustrate a vascular occlusive device which takes the form of anembolic coil 10 which may be placed along with other similar coils into a blood vessel or into an aneurysm in order to partially fill the aneurysm. More particularly, theembolic coil 10 is a typical embolic coil which comprises a helicallywound coil 12 formed from a platinum alloy wire wound into a helical configuration. The diameter of the wire is generally in the range of about 0.0007 inches to about 0.008 inches and the outer diameter of thecoil 12 is preferably in a range of about 0.003 inches to about 0.055 inches. While the particularembolic coil 12 illustrated inFIGS. 1 and 2 is shown as being a straight, helically wound coil, it should be appreciated that embolic coils are formed in various configurations and may take the form of a helix, a random shaped configuration or even a coil within a coil. - Preferably the
embolic coil 10 includes aweld bead 14 which is attached to the distal end of the coil for providing a less traumatic distal end for theembolic coil 10. In addition, theembolic coil 10 includes acylindrical headpiece 16 which is placed into the lumen of the helicallywound coil 12 at the proximal end of the coil and is held in place by anadhesive material 18 interposed between thecylindrical headpiece 16 and thehelical coil 12. The construction of theembolic coil 10 and an associated hydraulic deployment system for placing the embolic coil within an aneurysm is disclosed in more detail in U.S. patent application Ser. No. 10/102,154, entitled, “Small Diameter Embolic Coil Hydraulic Deployment System,” filed Mar. 19, 2002, assigned to the same assignee of the present invention and is hereby incorporated by reference. -
FIG. 2 illustrates in more detail abioactive agent 20, and anouter barrier 22 which is disposed upon thebioactive agent 20 for preventing the activation of the bioactive agent until such time as an election is made to activate the bioactive agent. More particularly, thebioactive agent 20, which may take the form of a thrombogenic agent, i.e. an agent which serves to increase or promote the growth and adhesion of thrombus onto the surface of theembolic coil 10, is coated onto the outer surface of thecoil 12. While the bioactive agent may take the form of a thrombogenic agent, it should be understood that the bioactive agent may take any form which would induce a desired reaction bodily tissue. For example, the bioactive agent may serve to cause blood to clot onto the surface of theembolic coil 10, it may serve to enhance the adhesion of thrombus onto the surface of the embolic coil, or it may serve to cause adjacent embolic coils to become bonded to each other through adhesion by components of blood. It should be appreciated that there are many other reactions which might exist between the bioactive agent and bodily tissue which would be desirable. - The
outer barrier 22 takes the form of a coating which is disposed upon thebioactive agent 20 and serves to insulate the bioactive agent from adjacent bodily fluid until such time as a decision is made by a physician to activate theouter barrier 22. Theouter barrier 22 takes the form of a material which is inert to bodily fluid, but which dissolves and exposes thebioactive agent 20 when theouter barrier 22 is subjected to an external agent. - In a preferred embodiment, the
bioactive agent 20 is comprised of polyglycolic acid, theouter barrier 22 is comprised of ethylene vinyl alcohol and the external agent for dissolving theouter barrier 22 is dimethyl sulfoxide (DMSO) which serves to dissolve theouter barrier 22 to thereby expose thebioactive agent 20. - It should be appreciated that there are numerous materials which would serve as a bioactive agent, an outer barrier and an external agent, some of which are indicated hereinafter. It is important, however, that the external agent be inert to bodily fluids, such as being non-water soluble, such as blood, in order to prevent the
outer barrier 22 from dissolving and exposing thebioactive agent 20 until such time as an election is made by a physician to activate theouter barrier 22. -
FIGS. 3A through 3C generally illustrate a method of utilizing the present invention. More particularly,FIG. 3A illustrates adelivery catheter 24 having anembolic coil 10 placed in the distal end of the catheter for delivery into ananeurysm 26.FIG. 3B illustrates thedelivery catheter 24 being used to position multiple vascular occlusive coils including a finalembolic coil 28 into theaneurysm 26.FIG. 3C illustrates the application of anexternal agent 30, which may take the form of a solvent for dissolving theouter barrier 22 to thereby activate theouter barrier 22 to expose at least a portion of thebioactive agent 20. - It may be desirable to place all of the vascular occlusive coils into the
aneurysm 26 prior to applying theexternal agent 30, however, another approach is that of placing a single coil into the aneurysm and thereafter activating that single coil, placing a second coil into the aneurysm and thereafter activating the second coil and so forth until all of the coils have been properly placed into the aneurysm. As may be appreciated, the advantage of the subject invention over prior devices is that the physician may determine at what point in time during the process of “filling” an aneurysm the physician elects to activate a coil as opposed to having no control over the time in which the coils become activated. - The bioactive agent may take the form of any material or surface which when placed into the body causes or inhibits a reaction with a bodily substance. For example, the bioactive agent may be a thrombus inducing material, or surface when placed within a blood vessel induces the growth of thrombus onto the surface of the bioactive agent or where the bioactive agent is a thrombolitic agent to inhibit the growth of tissue. The bioactive agent could take the form of a material which causes blood to clot onto the surface of the material, a material which produces an immune response, a material which releases a human growth factor, a material which promotes endothelization, etcetera. Another example of a bioactive agent is a pharmacologic agent which is inactive until the barrier is dissolved, or removed, or is modified, by an external source to expose the pharmacological agent to the body. A preferred bioactive agent to be used with a vascular occlusive coil is polyglycolic acid which promotes the growth of tissue.
- The outer barrier may take the form of a coating applied to the bioactive agent, or a substance added to the bioactive agent, which causes the bioactive agent to be substantially non-reactive with bodily fluids until such time as the outer barrier is acted upon by an external agent. A preferred outer barrier to be used with a vascular occlusive coil is a coating of ethylene vinyl alcohol which serves to encase the bioactive agent until a solvent is applied to the coating to thereby dissolve, or remove, or modify the barrier in order to expose the bioactive agent to the body.
- The external agent may take the form of any agent which when applied to the outer barrier causes the outer barrier to become ineffective in preventing a reaction between the bioactive agent and bodily tissue. The external agent may take the form of a solvent for dissolving the outer barrier in order to expose the bioactive agent, or it may take the form of a substance which reacts with the bioactive agent in order to activate the bioactive agent. The external agent may for example be a liquid material or it may be a source of heat or a laser source for dissolving the outer barrier, or removing all or part of the outer barrier or for modifying the outer barrier such as for example biologically modifying the outer barrier in order to activate receptors of the bioactive agent, in order to expose the bioactive agent to bodily tissue. A preferred external agent for a vascular occlusive coil is dimethyl sulfoxide which serves as a solvent to dissolve an outer barrier coating comprising ethylene vinyl alcohol so as to permit the bioactive agent to come into contact with bodily tissue. By “bodily tissue” is meant any substance within the human body and includes blood, fibrous growth within blood vessels, etcetera.
- Although a preferred embodiment of the present invention has been described, it is to be understood that various modifications may be made by those skilled in the art without departing from the scope of the claims which follow.
Claims (10)
1. An implantable vascular occlusive device for therapeutic treatment of a patient by aiding in occluding blood in a selected portion of the vasculature or in filling an aneurysm, comprising:
a vascular occlusive embolic coil;
a thrombus-inducing bioactive agent disposed on said embolic coil; and,
an outer barrier disposed on said bioactive agent to prevent exposure of said thrombus-inducing bioactive agent to bodily fluid when said vascular occlusive device is inserted into a blood vessel, said outer barrier exhibiting the characteristic of being substantially inert to bodily fluid but dissolving when exposed to an external agent, wherein the outer barrier is a coating, and wherein said characteristic of being substantially inert further comprises being non-water soluble.
2. The implantable vascular occlusive device of claim 1 , wherein said bioactive agent comprises polyglycolic acid, and said outer barrier coating comprises ethylene vinyl alcohol.
3. The implantable vascular occlusive device of claim 2 , wherein said external agent is comprised of dimethyl sulfoxide.
4. The implantable vascular occlusive device of claim 1 , wherein said embolic coil takes the form of a helically wound metallic coil.
5. The implantable vascular occlusive device of claim 1 , the embolic coil further comprising a rounded distal tip.
6. The implantable vascular occlusive device of claim 1 , the embolic coil further comprising a proximal cylindrical headpiece positioned within a lumen defined by the embolic coil.
7. An implantable vascular occlusive device for therapeutic treatment of a patient by aiding in occluding blood in a selected portion of the vasculature or in filling an aneurysm, comprising:
a vascular occlusive embolic coil;
a thrombus-inducing bioactive agent disposed on said embolic coil; and,
an outer barrier comprising an activatable agent, said outer barrier covering said thrombus-inducing bioactive agent and exhibiting the characteristics of substantially preventing a reaction between the bioactive agent and bodily fluid when said vascular occlusive device is inserted into a blood vessel and permitting a reaction between the bioactive agent and bodily fluid upon activation by an external source.
8. A method of treating an aneurysm comprising the steps of:
providing a vascular occlusive device comprising a support member, a bioactive agent disposed on said support member, and a barrier exhibiting the characteristic of normally preventing a reaction between the bioactive agent and a bodily fluid and of exposing a portion of said bioactive agent when an external agent is applied to said barrier;
inserting a delivery catheter into a blood vessel;
advancing the distal tip of the delivery catheter through the blood vessel until the distal tip is adjacent an aneurysm within the blood vessel;
delivering said vascular occlusive device with the delivery catheter into an aneurysm; and,
applying said external agent through the catheter and into the aneurysm to thereby activate said barrier to expose said bioactive agent to bodily tissue to thereby cause a reaction between the bioactive agent and the bodily tissue.
9. A method of treating an aneurysm comprising the steps of:
providing a vascular occlusive device comprising a support member having a bioactive surface which reacts with bodily tissue and having a barrier which exhibits the characteristic of normally inhibiting a reaction between said bioactive surface of said vascular occlusive/device and bodily tissue;
inserting a delivery catheter into a blood vessel;
advancing the distal tip of the delivery catheter through the blood vessel until the distal tip is adjacent an aneurysm within the blood vessel;
delivering said vascular occlusive device with the delivery catheter into an aneurysm; and,
applying an external agent through the catheter and into the aneurysm to thereby activate said barrier and thus expose said bioactive surface to bodily tissue to thereby cause a reaction between the bioactive surface and the bodily tissue.
10. A method of delivering a bioactive agent to a desired location in a blood vessel comprising the steps:
providing a support member having a bioactive surface which reacts with bodily tissue and have a barrier which exhibits the characteristic of normally inhibiting a reaction between said bioactive surface of said support member and bodily tissue;
inserting a delivery catheter into a blood vessel;
advancing the distal tip of the delivery catheter through the blood vessel until the distal tip is adjacent the desired location within the blood vessel;
delivering said support member with the delivery catheter to the desired location; and,
applying an external agent through the catheter to said support member to thereby activate said barrier and thus expose said bioactive surface to bodily tissue to thereby cause a reaction between the bioactive surface and the bodily tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/821,340 US20070255253A1 (en) | 2003-12-17 | 2007-06-22 | Activatable bioactive vascular occlusive device and method of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/738,473 US7294123B2 (en) | 2003-12-17 | 2003-12-17 | Activatable bioactive vascular occlusive device and method of use |
US11/821,340 US20070255253A1 (en) | 2003-12-17 | 2007-06-22 | Activatable bioactive vascular occlusive device and method of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,473 Division US7294123B2 (en) | 2003-12-17 | 2003-12-17 | Activatable bioactive vascular occlusive device and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070255253A1 true US20070255253A1 (en) | 2007-11-01 |
Family
ID=34552785
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,473 Expired - Lifetime US7294123B2 (en) | 2003-12-17 | 2003-12-17 | Activatable bioactive vascular occlusive device and method of use |
US11/821,340 Abandoned US20070255253A1 (en) | 2003-12-17 | 2007-06-22 | Activatable bioactive vascular occlusive device and method of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/738,473 Expired - Lifetime US7294123B2 (en) | 2003-12-17 | 2003-12-17 | Activatable bioactive vascular occlusive device and method of use |
Country Status (5)
Country | Link |
---|---|
US (2) | US7294123B2 (en) |
EP (1) | EP1547530B1 (en) |
JP (1) | JP4615305B2 (en) |
CA (1) | CA2489493A1 (en) |
DE (1) | DE602004021896D1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095378A1 (en) * | 2013-12-17 | 2015-06-25 | Board Of Regents Of The University Of Nebraska | Platform device and method of use to assist in anastomosis formation |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10233085B4 (en) | 2002-07-19 | 2014-02-20 | Dendron Gmbh | Stent with guide wire |
US8425549B2 (en) | 2002-07-23 | 2013-04-23 | Reverse Medical Corporation | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
US6979330B2 (en) * | 2003-03-13 | 2005-12-27 | Boston Scientific Scimed, Inc. | System for indirectly ablating tissue using implanted electrode devices |
US7247159B2 (en) * | 2004-04-08 | 2007-07-24 | Cordis Neurovascular, Inc. | Activatable bioactive vascular occlusive device |
US20060155324A1 (en) * | 2005-01-12 | 2006-07-13 | Porter Stephen C | Vaso-occlusive devices with attached polymer structures |
US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
US20080269774A1 (en) | 2006-10-26 | 2008-10-30 | Chestnut Medical Technologies, Inc. | Intracorporeal Grasping Device |
US8088140B2 (en) | 2008-05-19 | 2012-01-03 | Mindframe, Inc. | Blood flow restorative and embolus removal methods |
US11337714B2 (en) | 2007-10-17 | 2022-05-24 | Covidien Lp | Restoring blood flow and clot removal during acute ischemic stroke |
AU2009217354B2 (en) | 2008-02-22 | 2013-10-10 | Covidien Lp | Methods and apparatus for flow restoration |
US10716573B2 (en) | 2008-05-01 | 2020-07-21 | Aneuclose | Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm |
US10028747B2 (en) | 2008-05-01 | 2018-07-24 | Aneuclose Llc | Coils with a series of proximally-and-distally-connected loops for occluding a cerebral aneurysm |
CN102202582B (en) | 2008-09-04 | 2014-07-30 | 库拉希尔公司 | Inflatable device for enteric fistula treatment |
US9358140B1 (en) | 2009-11-18 | 2016-06-07 | Aneuclose Llc | Stent with outer member to embolize an aneurysm |
US9039749B2 (en) | 2010-10-01 | 2015-05-26 | Covidien Lp | Methods and apparatuses for flow restoration and implanting members in the human body |
US9211116B2 (en) | 2011-06-16 | 2015-12-15 | Curaseal Inc. | Fistula treatment devices and related methods |
CN107137114A (en) | 2011-06-17 | 2017-09-08 | 库拉希尔公司 | The device and method treated for fistula |
US9662120B2 (en) * | 2013-08-23 | 2017-05-30 | Cook Medical Technologies Llc | Detachable treatment device delivery system utilizing compression at attachment zone |
US10076399B2 (en) | 2013-09-13 | 2018-09-18 | Covidien Lp | Endovascular device engagement |
Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US5108407A (en) * | 1990-06-08 | 1992-04-28 | Rush-Presbyterian St. Luke's Medical Center | Method and apparatus for placement of an embolic coil |
US5122136A (en) * | 1990-03-13 | 1992-06-16 | The Regents Of The University Of California | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US5226911A (en) * | 1991-10-02 | 1993-07-13 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5304194A (en) * | 1991-10-02 | 1994-04-19 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5334210A (en) * | 1993-04-09 | 1994-08-02 | Cook Incorporated | Vascular occlusion assembly |
US5382259A (en) * | 1992-10-26 | 1995-01-17 | Target Therapeutics, Inc. | Vasoocclusion coil with attached tubular woven or braided fibrous covering |
US5639277A (en) * | 1995-04-28 | 1997-06-17 | Target Therapeutics, Inc. | Embolic coils with offset helical and twisted helical shapes |
US5658308A (en) * | 1995-12-04 | 1997-08-19 | Target Therapeutics, Inc. | Bioactive occlusion coil |
US5669931A (en) * | 1995-03-30 | 1997-09-23 | Target Therapeutics, Inc. | Liquid coils with secondary shape |
US5690671A (en) * | 1994-12-13 | 1997-11-25 | Micro Interventional Systems, Inc. | Embolic elements and methods and apparatus for their delivery |
US5695480A (en) * | 1996-07-29 | 1997-12-09 | Micro Therapeutics, Inc. | Embolizing compositions |
US5749894A (en) * | 1996-01-18 | 1998-05-12 | Target Therapeutics, Inc. | Aneurysm closure method |
US5750585A (en) * | 1995-04-04 | 1998-05-12 | Purdue Research Foundation | Super absorbent hydrogel foams |
US5820608A (en) * | 1993-09-29 | 1998-10-13 | Hercules Incorporated | Method for in vivo chemically triggered disintegration of medical device |
US5853418A (en) * | 1995-06-30 | 1998-12-29 | Target Therapeutics, Inc. | Stretch resistant vaso-occlusive coils (II) |
US5925062A (en) * | 1992-09-02 | 1999-07-20 | Board Of Regents, The University Of Texas System | Intravascular device |
US5935145A (en) * | 1998-02-13 | 1999-08-10 | Target Therapeutics, Inc. | Vaso-occlusive device with attached polymeric materials |
US5976162A (en) * | 1996-04-10 | 1999-11-02 | Target Therapeutics, Inc. | Soft-ended fibered micro vaso-occlusive devices |
US5980550A (en) * | 1998-06-18 | 1999-11-09 | Target Therapeutics, Inc. | Water-soluble coating for bioactive vasoocclusive devices |
US6124131A (en) * | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
US6146373A (en) * | 1997-10-17 | 2000-11-14 | Micro Therapeutics, Inc. | Catheter system and method for injection of a liquid embolic composition and a solidification agent |
US6187027B1 (en) * | 1995-04-28 | 2001-02-13 | Target Therapeutics, Inc. | Vaso-occlusive devices with heat secured polymer fiber |
US6187024B1 (en) * | 1998-11-10 | 2001-02-13 | Target Therapeutics, Inc. | Bioactive coating for vaso-occlusive devices |
US6280457B1 (en) * | 1999-06-04 | 2001-08-28 | Scimed Life Systems, Inc. | Polymer covered vaso-occlusive devices and methods of producing such devices |
US20020004681A1 (en) * | 1998-11-10 | 2002-01-10 | Clifford Teoh | Bioactive three loop coil |
US20020049503A1 (en) * | 2000-10-20 | 2002-04-25 | Michael Milbocker | Surgical repair of tissue defects |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US20020087184A1 (en) * | 1998-06-18 | 2002-07-04 | Eder Joseph C. | Water-soluble coating for bioactive devices |
US6423085B1 (en) * | 1998-01-27 | 2002-07-23 | The Regents Of The University Of California | Biodegradable polymer coils for intraluminal implants |
US6425914B1 (en) * | 1997-08-29 | 2002-07-30 | Target Therapeutics, Inc. | Fast-detaching electrically insulated implant |
US20020120297A1 (en) * | 2001-02-26 | 2002-08-29 | Shadduck John H. | Vaso-occlusive implants for interventional neuroradiology |
US20020123801A1 (en) * | 2000-12-28 | 2002-09-05 | Pacetti Stephen D. | Diffusion barrier layer for implantable devices |
US20020143348A1 (en) * | 2001-03-30 | 2002-10-03 | Wallace Michael P. | Embolic devices capable of in-situ reinforcement |
US20020151915A1 (en) * | 1998-03-10 | 2002-10-17 | Grant Hieshima | Small diameter embolic coil hydraulic deployment system |
US6494884B2 (en) * | 2001-02-09 | 2002-12-17 | Concentric Medical, Inc. | Methods and devices for delivering occlusion elements |
US20020193823A1 (en) * | 2001-05-29 | 2002-12-19 | Wallace Michael P. | Absorbable implantable vaso-occlusive member |
US20030017190A1 (en) * | 2000-12-22 | 2003-01-23 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US20030074049A1 (en) * | 2000-08-25 | 2003-04-17 | Kensey Nash Corporation | Covered stents and systems for deploying covered stents |
US20030093147A1 (en) * | 2001-11-13 | 2003-05-15 | Ogle Matthew F. | Medical devices that stimulate growth factor production |
US20030109824A1 (en) * | 2001-11-07 | 2003-06-12 | Microvena Corporation | Distal protection device with local drug delivery to maintain patency |
US6599275B1 (en) * | 1996-06-04 | 2003-07-29 | Cook Incorporated | Implantable medical device |
US6602261B2 (en) * | 1999-10-04 | 2003-08-05 | Microvention, Inc. | Filamentous embolic device with expansile elements |
US20030171770A1 (en) * | 2002-03-08 | 2003-09-11 | Kusleika Richard S. | Distal protection devices having controllable wire motion |
US20040093014A1 (en) * | 1998-11-10 | 2004-05-13 | Hanh Ho | Bioactive components for incorporation with vaso-occlusive members |
US6764505B1 (en) * | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US20050137568A1 (en) * | 2003-12-17 | 2005-06-23 | Jones Donald K. | Activatable bioactive implantable medical device and method of use |
US20050228435A1 (en) * | 2004-04-08 | 2005-10-13 | Lorenzo Juan A | Activatable bioactive vascular occlusive device |
US7101394B2 (en) * | 2002-05-02 | 2006-09-05 | Boston Scientific Scimed, Inc. | Energetically-controlled delivery of biologically active material from an implanted medical device |
US7175611B2 (en) * | 2002-06-05 | 2007-02-13 | Mark Alan Mitchnick | Antimicrobial release system |
US7186826B2 (en) * | 2002-02-01 | 2007-03-06 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02152469A (en) * | 1988-12-02 | 1990-06-12 | Olympus Optical Co Ltd | Drug capsule |
US5122138A (en) * | 1990-11-28 | 1992-06-16 | Manwaring Kim H | Tissue vaporizing accessory and method for an endoscope |
US5366454A (en) * | 1993-03-17 | 1994-11-22 | La Corporation De L'ecole Polytechnique | Implantable medication dispensing device |
US5890871A (en) * | 1997-12-10 | 1999-04-06 | Caterpillar Inc. | Latching mechanism for a quick coupler |
US6015424A (en) * | 1998-04-28 | 2000-01-18 | Microvention, Inc. | Apparatus and method for vascular embolization |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
CN100377749C (en) * | 1998-12-31 | 2008-04-02 | 血管技术药物公司 | Stent grafts with bioactive coatings |
WO2001003666A2 (en) * | 1999-07-12 | 2001-01-18 | Scimed Life Systems, Inc. | Liquid based vaso-occlusive compositions |
US20040029952A1 (en) * | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6251136B1 (en) * | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
AU2002224453A1 (en) * | 2000-10-11 | 2002-04-22 | Microchips, Inc. | Microchip reservoir devices and facilitated corrosion of electrodes |
-
2003
- 2003-12-17 US US10/738,473 patent/US7294123B2/en not_active Expired - Lifetime
-
2004
- 2004-12-09 CA CA002489493A patent/CA2489493A1/en not_active Abandoned
- 2004-12-16 DE DE602004021896T patent/DE602004021896D1/en active Active
- 2004-12-16 JP JP2004364877A patent/JP4615305B2/en not_active Expired - Fee Related
- 2004-12-16 EP EP04257859A patent/EP1547530B1/en not_active Expired - Fee Related
-
2007
- 2007-06-22 US US11/821,340 patent/US20070255253A1/en not_active Abandoned
Patent Citations (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US5122136A (en) * | 1990-03-13 | 1992-06-16 | The Regents Of The University Of California | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US5108407A (en) * | 1990-06-08 | 1992-04-28 | Rush-Presbyterian St. Luke's Medical Center | Method and apparatus for placement of an embolic coil |
US5226911A (en) * | 1991-10-02 | 1993-07-13 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5304194A (en) * | 1991-10-02 | 1994-04-19 | Target Therapeutics | Vasoocclusion coil with attached fibrous element(s) |
US5925062A (en) * | 1992-09-02 | 1999-07-20 | Board Of Regents, The University Of Texas System | Intravascular device |
US5382259A (en) * | 1992-10-26 | 1995-01-17 | Target Therapeutics, Inc. | Vasoocclusion coil with attached tubular woven or braided fibrous covering |
US5334210A (en) * | 1993-04-09 | 1994-08-02 | Cook Incorporated | Vascular occlusion assembly |
US5820608A (en) * | 1993-09-29 | 1998-10-13 | Hercules Incorporated | Method for in vivo chemically triggered disintegration of medical device |
US5690671A (en) * | 1994-12-13 | 1997-11-25 | Micro Interventional Systems, Inc. | Embolic elements and methods and apparatus for their delivery |
US5669931A (en) * | 1995-03-30 | 1997-09-23 | Target Therapeutics, Inc. | Liquid coils with secondary shape |
US5750585A (en) * | 1995-04-04 | 1998-05-12 | Purdue Research Foundation | Super absorbent hydrogel foams |
US6187027B1 (en) * | 1995-04-28 | 2001-02-13 | Target Therapeutics, Inc. | Vaso-occlusive devices with heat secured polymer fiber |
US5639277A (en) * | 1995-04-28 | 1997-06-17 | Target Therapeutics, Inc. | Embolic coils with offset helical and twisted helical shapes |
US5853418A (en) * | 1995-06-30 | 1998-12-29 | Target Therapeutics, Inc. | Stretch resistant vaso-occlusive coils (II) |
US5658308A (en) * | 1995-12-04 | 1997-08-19 | Target Therapeutics, Inc. | Bioactive occlusion coil |
US5749894A (en) * | 1996-01-18 | 1998-05-12 | Target Therapeutics, Inc. | Aneurysm closure method |
US6024754A (en) * | 1996-01-18 | 2000-02-15 | Target Therapeutics Inc. | Aneurysm closure method |
US5976162A (en) * | 1996-04-10 | 1999-11-02 | Target Therapeutics, Inc. | Soft-ended fibered micro vaso-occlusive devices |
US6599275B1 (en) * | 1996-06-04 | 2003-07-29 | Cook Incorporated | Implantable medical device |
US5695480A (en) * | 1996-07-29 | 1997-12-09 | Micro Therapeutics, Inc. | Embolizing compositions |
US6425914B1 (en) * | 1997-08-29 | 2002-07-30 | Target Therapeutics, Inc. | Fast-detaching electrically insulated implant |
US6146373A (en) * | 1997-10-17 | 2000-11-14 | Micro Therapeutics, Inc. | Catheter system and method for injection of a liquid embolic composition and a solidification agent |
US6423085B1 (en) * | 1998-01-27 | 2002-07-23 | The Regents Of The University Of California | Biodegradable polymer coils for intraluminal implants |
US5935145A (en) * | 1998-02-13 | 1999-08-10 | Target Therapeutics, Inc. | Vaso-occlusive device with attached polymeric materials |
US6287318B1 (en) * | 1998-02-13 | 2001-09-11 | Target Therapeutics, Inc. | Vaso-occlusive device with attached polymeric materials |
US20020151915A1 (en) * | 1998-03-10 | 2002-10-17 | Grant Hieshima | Small diameter embolic coil hydraulic deployment system |
US6299627B1 (en) * | 1998-06-18 | 2001-10-09 | Target Therapeutics, Inc. | Water-soluble coating for bioactive vasoocclusive devices |
US20020087184A1 (en) * | 1998-06-18 | 2002-07-04 | Eder Joseph C. | Water-soluble coating for bioactive devices |
US5980550A (en) * | 1998-06-18 | 1999-11-09 | Target Therapeutics, Inc. | Water-soluble coating for bioactive vasoocclusive devices |
US6124131A (en) * | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
US20040093014A1 (en) * | 1998-11-10 | 2004-05-13 | Hanh Ho | Bioactive components for incorporation with vaso-occlusive members |
US6231590B1 (en) * | 1998-11-10 | 2001-05-15 | Scimed Life Systems, Inc. | Bioactive coating for vaso-occlusive devices |
US6187024B1 (en) * | 1998-11-10 | 2001-02-13 | Target Therapeutics, Inc. | Bioactive coating for vaso-occlusive devices |
US20020004681A1 (en) * | 1998-11-10 | 2002-01-10 | Clifford Teoh | Bioactive three loop coil |
US6280457B1 (en) * | 1999-06-04 | 2001-08-28 | Scimed Life Systems, Inc. | Polymer covered vaso-occlusive devices and methods of producing such devices |
US6602261B2 (en) * | 1999-10-04 | 2003-08-05 | Microvention, Inc. | Filamentous embolic device with expansile elements |
US20030074049A1 (en) * | 2000-08-25 | 2003-04-17 | Kensey Nash Corporation | Covered stents and systems for deploying covered stents |
US20020049503A1 (en) * | 2000-10-20 | 2002-04-25 | Michael Milbocker | Surgical repair of tissue defects |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US20030017190A1 (en) * | 2000-12-22 | 2003-01-23 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
US20020123801A1 (en) * | 2000-12-28 | 2002-09-05 | Pacetti Stephen D. | Diffusion barrier layer for implantable devices |
US6494884B2 (en) * | 2001-02-09 | 2002-12-17 | Concentric Medical, Inc. | Methods and devices for delivering occlusion elements |
US20020120297A1 (en) * | 2001-02-26 | 2002-08-29 | Shadduck John H. | Vaso-occlusive implants for interventional neuroradiology |
US20020143348A1 (en) * | 2001-03-30 | 2002-10-03 | Wallace Michael P. | Embolic devices capable of in-situ reinforcement |
US6764505B1 (en) * | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US20020193823A1 (en) * | 2001-05-29 | 2002-12-19 | Wallace Michael P. | Absorbable implantable vaso-occlusive member |
US20030109824A1 (en) * | 2001-11-07 | 2003-06-12 | Microvena Corporation | Distal protection device with local drug delivery to maintain patency |
US20030093147A1 (en) * | 2001-11-13 | 2003-05-15 | Ogle Matthew F. | Medical devices that stimulate growth factor production |
US7186826B2 (en) * | 2002-02-01 | 2007-03-06 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds and uses thereof |
US20030171770A1 (en) * | 2002-03-08 | 2003-09-11 | Kusleika Richard S. | Distal protection devices having controllable wire motion |
US7101394B2 (en) * | 2002-05-02 | 2006-09-05 | Boston Scientific Scimed, Inc. | Energetically-controlled delivery of biologically active material from an implanted medical device |
US7175611B2 (en) * | 2002-06-05 | 2007-02-13 | Mark Alan Mitchnick | Antimicrobial release system |
US20050137568A1 (en) * | 2003-12-17 | 2005-06-23 | Jones Donald K. | Activatable bioactive implantable medical device and method of use |
US20050137569A1 (en) * | 2003-12-17 | 2005-06-23 | Jones Donald K. | Activatable bioactive implantable medical device and method of use |
US20050137623A1 (en) * | 2003-12-17 | 2005-06-23 | Jones Donald K. | Activatable foam expandable implantable medical device and method of use |
US20050228435A1 (en) * | 2004-04-08 | 2005-10-13 | Lorenzo Juan A | Activatable bioactive vascular occlusive device |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095378A1 (en) * | 2013-12-17 | 2015-06-25 | Board Of Regents Of The University Of Nebraska | Platform device and method of use to assist in anastomosis formation |
US10433847B2 (en) | 2013-12-17 | 2019-10-08 | The Board Of Regents Of The University Of Nebraska | Platform device and method of use to assist in anastomosis formation |
US11160555B2 (en) | 2013-12-17 | 2021-11-02 | Board Of Regents Of The University Of Nebraska | Platform device and method of use to assist in anastomosis formation |
Also Published As
Publication number | Publication date |
---|---|
EP1547530B1 (en) | 2009-07-08 |
JP2005177490A (en) | 2005-07-07 |
US20050149107A1 (en) | 2005-07-07 |
EP1547530A1 (en) | 2005-06-29 |
CA2489493A1 (en) | 2005-06-17 |
DE602004021896D1 (en) | 2009-08-20 |
US7294123B2 (en) | 2007-11-13 |
JP4615305B2 (en) | 2011-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070255253A1 (en) | Activatable bioactive vascular occlusive device and method of use | |
EP1584298B1 (en) | Activatable bioactive vascular occlusive device comprising fibers | |
US6613074B1 (en) | Endovascular aneurysm embolization device | |
US7309345B2 (en) | Method and system for delivering an implant utilizing a lumen reducing member | |
CA2551376C (en) | Stretch resistant embolic coil delivery system with mechanical release mechanism | |
US8211141B2 (en) | Stretch resistant design for embolic coils with stabilization bead | |
US8034073B2 (en) | Stretch resistant embolic coil | |
CA2490426C (en) | Activatable bioactive implantable medical device and method of use | |
CA2490440C (en) | Activatable foam expandable implantable medical device and method of use | |
EP1543783B1 (en) | Activable bioactive implantable medical device. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CODMAN & SHURTLEFF, INC., MASSACHUSETTS Free format text: MERGER;ASSIGNOR:CORDIS NEUROVASCULAR, INC.;REEL/FRAME:023032/0233 Effective date: 20081216 Owner name: CODMAN & SHURTLEFF, INC.,MASSACHUSETTS Free format text: MERGER;ASSIGNOR:CORDIS NEUROVASCULAR, INC.;REEL/FRAME:023032/0233 Effective date: 20081216 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |